Tubulis

Tubulis is a German clinical-stage biotechnology company focused on the design and development of antibody-drug conjugates (ADCs). Founded in 2018 and headquartered at the Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried near Munich, the company has built a proprietary technology suite that aims to expand the therapeutic horizon of ADCs. According to its official website, Tubulis generates "uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models." The company's pipeline is led by two clinical-stage ADC candidates: TUB-040, which targets NaPi2b, and TUB-030, which is directed against 5T4. Both are being evaluated in the clinic in high-need solid tumor indications. Tubulis states that it intends to solidify its leadership position by continuing to innovate on all aspects of ADC design, leveraging its proprietary platform technologies, with the goal of expanding the therapeutic potential of this drug class for its own pipeline, its partners, and patients. Tubulis operates from three sites. Its headquarters at the IZB in Munich leverages cutting-edge research infrastructure. It also has a presence at the Cambridge Innovation Center in Cambridge, Massachusetts, through Tubulis, Inc., connecting with the Boston-area biotech ecosystem. In addition, Tubulis Sàrl is located at the Biopôle in Lausanne, Switzerland, drawing on Switzerland's life sciences expertise and European biotech talent. The company is led by CEO Dr. Dominik Schumacher, who co-founded Tubulis in 2018. Prior to founding the company, Schumacher worked at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and as a group leader at Ludwig Maximilian University (LMU) in Munich. He obtained his PhD from Humboldt University of Berlin. In 2019, he was recognized as one of MIT's Innovators Under 35. The team brings together expertise in chemistry, antibody technologies, bioconjugation, business, drug development, and clinical oncology. Tubulis is a private, venture-backed company. It maintains an active presence at major scientific and medical conferences, including the World ADC, ESGO Congress, Novel Conjugates Summit, European Lung Cancer Congress, SGO Annual Meeting, AACR Annual Meeting, and ASCO Annual Meeting, reflecting its engagement with the global oncology research and clinical community.

Tubulis was founded in 2018 as a spin-out from research conducted at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and Ludwig Maximilian University (LMU) in Munich. Dr. Dominik Schumacher, who had worked at the FMP and as a group leader at LMU, co-founded the company and serves as its CEO. From the early founding phase, Schumacher secured several prestigious start-up awards for Tubulis, and in 2019 he was recognized as one of MIT's Innovators Under 35. The company established its headquarters at the Innovation and Start-up Center for Biotechnology (IZB) in Planegg-Martinsried near Munich, leveraging the site's cutting-edge research infrastructure. Over time, Tubulis expanded its footprint internationally, adding a presence at the Cambridge Innovation Center in Cambridge, Massachusetts, through Tubulis, Inc., and a Swiss entity, Tubulis Sàrl, at the Biopôle in Lausanne. These sites connect the company to the Boston-area biotech ecosystem and to Switzerland's life sciences talent pool, respectively. Tubulis has developed a proprietary technology suite for antibody-drug conjugate (ADC) design. According to its official website, the company generates "uniquely matched antibody-drug conjugates with superior biophysical properties that have demonstrated durable on-tumor delivery and long-lasting anti-tumor activity in preclinical models." Its pipeline has advanced two lead programs into the clinic: TUB-040, targeting NaPi2b, and TUB-030, directed against 5T4. Both are being evaluated in high-need solid tumor indications. The company states that it will solidify its leadership position by continuing to innovate on all aspects of ADC design, leveraging its proprietary platform technologies, with the goal of expanding the therapeutic potential of this drug class for its pipeline, its partners, and patients. Tubulis maintains an active conference presence, with planned participation in events such as the 16th Annual World ADC in London, the ESGO Congress in Copenhagen, the 5th Annual Novel Conjugates Summit in Boston, the European Lung Cancer Congress in Copenhagen, the SGO Annual Meeting on Women's Cancer in San Juan, the AACR Annual Meeting in San Diego, and the ASCO Annual Meeting in Chicago, all scheduled for 2026.

• 2026

  Tubulis plans participation in major conferences including World ADC, ESGO, Novel Conjugates Summit, ELCC, SGO, AACR, and ASCO.

• 2019

  Dr. Dominik Schumacher recognized as one of MIT's Innovators Under 35.

• 2018

  Tubulis founded as a spin-out; Dr. Dominik Schumacher co-founds the company.

• TUB-040 (targeting NaPi2b) and TUB-030 (targeting 5T4) advance into clinical evaluation in high-need solid tumor indications.

Clinical-stage biotechnology company developing next-generation antibody-drug conjugates with superior biophysical properties for high-need solid and hematologic tumors.

• TUB-040

  Clinical-stage ADC candidate targeting NaPi2b for high-need solid tumor indications.

• TUB-030

  Clinical-stage ADC candidate directed against 5T4 for high-need solid tumor indications.

• Tubulis ADC platform technologies

  Proprietary technology suite for designing uniquely matched antibody-drug conjugates with superior biophysical properties.

1. 1Startseite - Tubulistubulis.com
2. 2Meet the Team behind Tubulis - Tubulistubulis.com
3. 3Tubulis (Germany) - Wikidatawikidata.org